Ipca Laboratories Ltd logo

Ipca Laboratories Ltd

IPCALAB NSE

Key Fundamentals

MidcapPharmaceuticalsHealthcare
Market Cap
₹48,260 Cr
Volatility
Moderate
P/E Ratio
36.45
EBITDA
₹2,153 Cr
Return on Equity
12.51%
Debt to Equity
0.1
Book Value
₹317.84
EPS
₹23.14
52W High
₹1,945.1
52W Low
₹1,251.6

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Ipca Laboratories Ltd insights

48 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

1
  • Company has reduced debt.

Weaknesses

2
  • Stock is trading at 5.93 times its book value
  • Company has a low return on equity of 12.9% over last 3 years.

Growth Rate

Revenue Growth
8.73% ↘
Net Income Growth
51.29% ↗
Cash Flow Change
-13.57% ↘
ROE
33.23% ↘
ROCE
26.29% ↘
EBITDA Margin (Avg.)
8.84% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 3d ago
AI opinion · based on fundamentals
Risk medium

Ipca Laboratories trades at a market cap of ₹44,370 Cr with a PE of 33.2x and has delivered 54% TTM profit growth alongside 11% TTM sales growth. The company has reduced debt but carries a price-to-book of 5.65x with a 3-year average ROE of approximately 13%.

Bull Case 8
  • TTM profit growth of 54% signals a strong earnings recovery and improved operational leverage
  • 3-year compounded profit CAGR of 37% demonstrates sustained earnings momentum beyond a single quarter
  • Company has actively reduced debt, strengthening its balance sheet and lowering financial risk
  • 10-year compounded sales CAGR of 13% reflects consistent top-line growth across business cycles
  • Last year ROE improved to 16% from a 3-year average of 13%, indicating improving capital efficiency
  • Stock CAGR of 32% over 1 year and 27% over 3 years shows strong market re-rating and price momentum
  • 10-year compounded profit CAGR of 30% demonstrates long-term earnings compounding ability
  • 5-year compounded sales CAGR of 12% shows resilient revenue growth even through pandemic disruptions
Bear Case 8
  • PE of 33.2x is elevated relative to the 3-year average ROE of 13%, implying high expectations already priced in
  • Price-to-book of 5.65x is rich for a pharma company with mid-teen ROE, leaving limited margin of safety
  • 3-year average ROE of 12.9% is modest for a company trading at such premium valuations
  • 5-year compounded profit CAGR of just 1% highlights that recent profit surge follows years of earnings stagnation
  • Dividend yield of only 0.33% offers minimal income cushion during potential market corrections
  • 10-year stock CAGR of 21% versus 5-year stock CAGR of 9% shows the stock underperformed significantly in the middle period
  • TTM sales growth of 11% lags behind TTM profit growth of 54%, suggesting margin expansion may not be sustainable at this pace
  • 5-year ROE average of 13% has not materially improved from the 10-year average of 14%, indicating structural capital efficiency has been flat

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 18h ago
Positives 1
  • FY27 EBITDA margin guided to 23% Aug 14

    Ipca Laboratories raised its FY27 EBITDA margin guidance to 23%, reflecting confidence in operational efficiency. The company plans capacity expansion in R&D and API facilities targeting US and European markets.

Neutral 2
  • AGM resolutions approved smoothly Aug 14

    Shareholders passed all resolutions at the 76th AGM including director re-appointments and dividend declaration, with promoter support.

  • Q1FY27 earnings call scheduled Aug 6

    Ipca Laboratories will host a Q1FY27 earnings conference call on August 14, 2026, following financial results announcement on August 13, 2026.

TL;DR: Ipca Laboratories is signaling confidence with a raised FY27 EBITDA margin guidance to 23% and plans for capacity expansion into US and European markets. No material headwinds emerged in the recent news cycle. Corporate governance actions at the AGM proceeded without controversy. The trend appears stable-to-improving, with the upcoming Q1FY27 results on Aug 13 being the next catalyst to watch.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1,585
2,034
2,053
2,033
2,093
2,355
2,245
2,247
2,309
2,556
2,392
2,388
2,788
Expenses
1,278
1,673
1,722
1,711
1,700
1,913
1,782
1,818
1,892
2,012
1,859
1,905
2,119
Operating Profit
308
361
331
322
393
441
463
429
416
545
533
484
670
OPM %
19%
18%
16%
16%
19%
19%
21%
19%
18%
21%
22%
20%
24%
Other Income
45
-1
91
-118
21
26
20
-179
33
-30
38
48
25
Interest
31
44
33
29
24
23
17
22
19
20
18
20
12
Depreciation
69
90
100
98
99
100
98
100
100
103
108
107
111
PBT
252
225
289
77
290
345
368
128
331
392
446
404
572
Tax %
34%
39%
23%
96%
31%
29%
25%
49%
29%
28%
18%
24%
26%
Net Profit
164
136
221
1
199
246
276
64
233
281
364
307
424
EPS in Rs
6.42
5.72
7.09
2.35
7.58
9.05
9.78
2.67
9.19
11.14
12.86
11.79
15.84
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
3,144
2,867
3,156
3,258
3,746
4,619
5,395
5,797
6,204
7,662
8,897
9,599
10,126
Expenses
2,604
2,573
2,705
2,803
3,051
3,715
3,843
4,472
5,272
6,338
7,166
7,609
7,894
Operating Profit
541
294
451
455
695
904
1,552
1,325
932
1,324
1,731
1,990
2,232
OPM %
17%
10%
14%
14%
19%
20%
29%
23%
15%
17%
19%
21%
22%
Other Income
32
21
11
41
56
65
59
54
123
17
-114
80
81
Interest
32
35
27
28
22
20
12
11
48
141
88
79
69
Depreciation
180
163
173
178
182
210
209
232
262
357
398
418
429
PBT
361
117
262
291
546
739
1,389
1,136
745
843
1,131
1,573
1,814
Tax %
28%
18%
26%
18%
19%
18%
17%
20%
34%
37%
30%
24%
—
Net Profit
254
93
195
239
442
604
1,141
890
479
523
785
1,184
1,375
EPS in Rs
10.07
3.69
7.71
9.49
17.6
23.99
44.94
34.85
18.58
21.57
29.08
44.98
51.63
Div. Payout %
5%
0%
6%
5%
9%
10%
9%
11%
22%
19%
14%
0%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
25
25
25
25
25
25
25
25
25
25
25
25
Reserves
2,183
2,234
2,430
2,663
3,097
3,602
4,676
5,467
5,817
6,307
6,923
8,038
Borrowings
935
867
716
628
465
501
265
807
1,481
1,438
1,363
809
Other Liabilities
669
765
788
799
961
1,130
1,099
1,338
1,300
3,326
3,432
3,477
Total Liabilities
3,812
3,892
3,960
4,116
4,549
5,258
6,066
7,637
8,623
11,097
11,744
12,350
Fixed Assets
1,800
2,014
1,983
1,953
1,940
2,059
2,072
2,418
2,751
4,554
4,267
4,627
CWIP
267
129
95
73
66
133
235
306
140
343
622
773
Investments
16
26
136
87
120
310
505
989
626
862
980
844
Other Assets
1,729
1,723
1,746
2,003
2,422
2,756
3,254
3,924
5,105
5,339
5,875
6,106
Total Assets
3,812
3,892
3,960
4,116
4,549
5,258
6,066
7,637
8,623
11,097
11,744
12,350
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
468
709
282
341
501
570
1,090
856
806
945
1,321
1,142
Investing
-689
-218
-149
-135
-165
-509
-521
-851
-725
-1,215
-870
-247
Financing
251
-462
-159
-130
-183
-137
-306
427
507
-553
-283
-754
Net Cash Flow
29
29
-26
75
153
-76
264
432
588
-823
169
142
Free Cash Flow
-207
463
147
206
322
277
731
380
347
543
551
486
CFO/OP
100
251
74
88
88
80
86
80
110
94
97
78
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
41
57
58
67
66
71
55
57
58
80
77
77
Inventory Days
293
289
290
286
316
294
337
337
276
350
336
353
Days Payable
97
145
130
137
154
135
140
101
83
110
111
122
Cash Conversion Cycle
237
200
218
216
228
229
251
293
251
321
302
308
Working Capital Days
68
61
74
80
88
88
103
102
71
111
101
109
ROCE %
14%
5%
9%
10%
16%
19%
31%
20%
11%
13%
15%
17%

Shareholding Pattern

As of Jun 2026
Promoters 44.72%
DIIs 37.37%
FIIs 10.73%
Public 5.76%
Others 1.42%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
46.29%
46.29%
46.29%
46.29%
46.29%
46.29%
46.29%
46.29%
46.29%
46.29%
46.29%
46.29%
46.30%
46.30%
46.30%
44.72%
44.72%
44.72%
44.72%
44.72%
44.72%
44.72%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.02%
0.02%
0.02%
0.00%
9.86%
0.00%
10.51%
10.85%
10.83%
11.07%
10.76%
10.67%
10.43%
10.63%
10.63%
10.73%
DIIs
24.49%
24.86%
25.00%
29.73%
32.41%
33.31%
33.29%
34.03%
33.55%
35.19%
35.05%
33.79%
34.37%
33.78%
34.23%
35.68%
36.06%
36.20%
36.77%
37.32%
37.45%
37.37%
Government
0.28%
0.22%
0.22%
0.24%
0.24%
0.24%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
8.74%
8.25%
7.61%
7.75%
7.79%
7.50%
7.44%
7.41%
7.26%
6.98%
7.14%
7.12%
7.13%
7.27%
6.93%
6.88%
6.81%
6.82%
6.55%
5.88%
5.79%
5.76%
Others
20.20%
20.39%
20.89%
15.99%
13.27%
12.66%
12.97%
12.26%
12.89%
11.54%
1.67%
12.80%
1.69%
1.79%
1.71%
1.65%
1.65%
1.59%
1.53%
1.44%
1.41%
1.42%
No. of Shareholders
1,00,626
1,05,428
95,239
1,06,779
1,15,335
1,10,818
1,11,043
1,08,177
1,10,296
99,889
95,930
82,809
81,165
84,753
82,975
90,189
88,306
85,582
82,870
77,673
82,184
82,060

Documents

Frequently Asked Questions about Ipca Laboratories Ltd

What does Ipca Laboratories Ltd do?
Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)
Where is Ipca Laboratories Ltd (IPCALAB) listed?
Ipca Laboratories Ltd is listed on the Indian stock exchanges. It is listed on NSE: IPCALAB and BSE: 524494. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Ipca Laboratories Ltd belong to?
Ipca Laboratories Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Ipca Laboratories Ltd?
Ipca Laboratories Ltd has a market capitalisation of approximately ₹48259.62 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Ipca Laboratories Ltd?
The Price-to-Earnings (PE) ratio of Ipca Laboratories Ltd is 36.45. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Ipca Laboratories Ltd?
Over the past 52 weeks, Ipca Laboratories Ltd has traded between a low of ₹1,251.6 and a high of ₹1,945.1. This range helps investors understand the stock's price volatility and recent trading levels.
Does Ipca Laboratories Ltd pay dividends?
Yes, Ipca Laboratories Ltd has a dividend yield of 0.32%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Ipca Laboratories Ltd?
Ipca Laboratories Ltd has a Return on Equity (ROE) of 12.51%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Ipca Laboratories Ltd on Tapetide?
On Tapetide, you can view Ipca Laboratories Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)

Website ipca.com
CEO Mr. Premchand Godha A.C. A., B. Com., CA
Employees 16,778
Listed 1995-02-01
Face Value ₹ 1
Issued Size 25,37,04,218

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List